- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Primary biliary cholangitis
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 372KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 74KB)
Ursodeoxycholic acid – March 2023
Ursodeoxycholic acid: Capsule 250 mg, Tablet 500 mg; Ursofalk®
Last updated
30 June 2023